FAQ: Aditxt Inc. (NASDAQ: ADTX) and Evofem Biosciences Acquisition Highlights

What is Aditxt Inc.?

Aditxt, Inc. is a social innovation platform accelerating promising health innovations, operating programs focused on immune health and precision health, and aiming to introduce a women’s health program through the acquisition of Evofem Biosciences.

Who is Saundra Pelletier and what award did she receive?

Saundra Pelletier is the CEO of Evofem Biosciences, Aditxt’s pending acquisition target, who received the Trailblazing Female Founders Award at the 2025 STIMULATE Conference for advancing women’s sexual and reproductive health.

What products does Evofem Biosciences develop?

Evofem Biosciences develops PHEXXI(R), a hormone-free contraceptive, and SOLOSEC(R), an oral treatment for bacterial vaginosis and trichomoniasis.

When is the acquisition of Evofem Biosciences by Aditxt expected to complete?

The acquisition is expected to complete in the second half of 2025, subject to several conditions including approval by Evofem’s shareholders and Aditxt raising sufficient capital.

What are the conditions for the acquisition to close?

Conditions include approval by Evofem’s shareholders and Aditxt raising approximately $17 million, with $15.2 million required to satisfy Evofem’s senior secured noteholder.

What is the significance of the Trailblazing Female Founders Award?

The award recognizes Saundra Pelletier’s contributions to advancing women’s sexual and reproductive health, coinciding with Say Vagina Month, a campaign to normalize conversations around vaginal health.

Where can I find more information about Aditxt Inc.?

The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX.

What is InvestorWire?

InvestorWire is a specialized communications platform focusing on advanced wire-grade press release syndication for private and public companies and the investment community, part of the Dynamic Brand Portfolio @ IBN.